SITC

Refuge Biotechnologies to Present During Multi-Targeted Therapeutic Platforms Program at The Annual Meeting of The Society for Immunotherapy of Cancer

Retrieved on: 
Wednesday, October 30, 2019
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Medicine, Articles, Branches of biology, Society for Immunotherapy of Cancer, SITC, Synthetic biology, Cancer immunotherapy, Immunotherapy

Refuge Biotechnologies, Inc. ("Refuge"), a synthetic biology company developing intelligent cell therapeutics for cancer immunotherapy, today announced that Francesco M. Marincola, M.D., chief scientific officer of Refuge, will present during the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting & Pre-Conference Programs (SITC 2019) .

Key Points: 
  • Refuge Biotechnologies, Inc. ("Refuge"), a synthetic biology company developing intelligent cell therapeutics for cancer immunotherapy, today announced that Francesco M. Marincola, M.D., chief scientific officer of Refuge, will present during the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting & Pre-Conference Programs (SITC 2019) .
  • Dr. Marincola will deliver a scientific overview detailing Refuges platform technology during the Novel Multi-Targeted Therapeutic Platform program, held November 6 at the Gaylord National Hotel & Convention Center in Maryland.
  • The overview will include recent data from Refuges proprietary receptor-dCas platform and its multi-functional therapeutic applications.
  • This capability has the potential to be combined with numerous therapeutic mechanisms in a single customizable treatment.

Nurix Therapeutics Announces Upcoming Scientific Presentation for its CBL-B Program at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)

Retrieved on: 
Tuesday, October 22, 2019
Branches of biology, Proteins, Posttranslational modification, Medicine, CBL, Cancer treatments, SITC, Society for Immunotherapy of Cancer, Ubiquitin, Cancer immunotherapy, Immunotherapy

SAN FRANCISCO, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a company developing therapies that control disease-causing proteins, today announced that it will present data on its wholly-owned, CBL-B small molecule drug development program at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019).

Key Points: 
  • SAN FRANCISCO, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a company developing therapies that control disease-causing proteins, today announced that it will present data on its wholly-owned, CBL-B small molecule drug development program at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019).
  • SITC is being held on November 6-10, 2019 at the Gaylord National Hotel and Convention Center in National Harbor, Maryland.
  • Pharmacological evaluation of the ubiquitin ligase CBL-B as a small molecule, tumor immunotherapy target

Unum Therapeutics Announces Data Presentation at the Upcoming Society for Immunotherapy of Cancer (SITC) Meeting

Retrieved on: 
Wednesday, October 2, 2019
Medicine, Clinical medicine, Medical specialties, Cancer treatments, Virotherapy, Society for Immunotherapy of Cancer, Cancer immunotherapy, SITC, GOT2, Immunotherapy

CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today announced acceptance of a presentation at the 34th annual meeting of the Society for Immunotherapy of Cancer (SITC) being held November 610, 2019 in National Harbor, Maryland.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today announced acceptance of a presentation at the 34th annual meeting of the Society for Immunotherapy of Cancer (SITC) being held November 610, 2019 in National Harbor, Maryland.
  • Our BOXR platform aims to discover novel transgenes co-expressed with chimeric-targeting receptors to improve T cell functionality in the solid tumor microenvironment, said Seth Ettenberg, Ph.D., Chief Scientific Officer of Unum.
  • At this years SITC meeting, we are pleased to present preclinical data from BOXR1030, our first product candidate from this platform, and the role of the addition of the GOT2 transgene to the BOXR1030 construct that was discovered as part of this effort.
  • Follow Unum Therapeutics on social media: @UnumRx , and LinkedIn .

Society for Immunotherapy of Cancer Publishes First Clinical Immunotherapy Treatment Guidelines for Squamous Cell Carcinoma of the Head and Neck

Retrieved on: 
Thursday, July 18, 2019
Medicine, RTT, Clinical medicine, Health, Society for Immunotherapy of Cancer, Cancer immunotherapy, Immunotherapy, Head and neck cancer, Cancer, SITC, Pembrolizumab

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) ," authored under the guidance of the SITC Cancer Immunotherapy Guidelines Head and Neck Cancer Subcommittee, was published in the Journal for ImmunoTherapy of Cancer (JITC) , the society's open access, peer-reviewed online journal.

Key Points: 
  • The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) ," authored under the guidance of the SITC Cancer Immunotherapy Guidelines Head and Neck Cancer Subcommittee, was published in the Journal for ImmunoTherapy of Cancer (JITC) , the society's open access, peer-reviewed online journal.
  • "Immunotherapies addressed an urgent need for new treatments for patients with squamous cell carcinoma of the head and neck (HNSCC), a disease setting that hadn't gained a new treatment option since 2006," said Robert L. Ferris, MD, PhD, chair of the SITC Cancer Immunotherapy Guidelines Head and Neck Cancers Subcommittee.
  • The SITC guidelines include expert consensus recommendations that serve to better inform clinicians regarding many aspects of patient management throughout treatment with immunotherapy.
  • "These immunotherapy and cancer experts have worked to create clinical practice immunotherapy guidelines which we are now extending into head and neck cancers.

Society for Immunotherapy of Cancer (SITC) Announces Recipients of 2019 Postdoctoral Cancer Immunotherapy Fellowship Awards

Retrieved on: 
Thursday, June 6, 2019
Medical specialties, Society for Immunotherapy of Cancer, Medicine, Health, SITC, Cancer immunotherapy

MILWAUKEE, Wis., June 6, 2019 /PRNewswire-PRWeb/ -- The Society for Immunotherapy of Cancer (SITC) is pleased to announce the recipients of three 2019 Fellowship Awards, which support the next generation of cancer immunotherapy and tumor immunology experts through dedicated funding of novel research.

Key Points: 
  • MILWAUKEE, Wis., June 6, 2019 /PRNewswire-PRWeb/ -- The Society for Immunotherapy of Cancer (SITC) is pleased to announce the recipients of three 2019 Fellowship Awards, which support the next generation of cancer immunotherapy and tumor immunology experts through dedicated funding of novel research.
  • This year's awards include the SITC-Amgen Cancer Immunotherapy in Hematologic Malignancies Fellowship Award (a one-year, $100,000 award), the SITC-AstraZeneca Immunotherapy in Lung Cancer (Early Stage NSCLC) Clinical Fellowship Award (a one-year, $100,000 award) and SITC's Holbrook Kohrt, MD, PhD Cancer Immunotherapy Translational Memorial Fellowship Award (sponsored by Genentech) (a one-year, $100,000 award).
  • "SITC is pleased to support the research of these next generation leaders within the cancer immunotherapy field," said SITC President Mario Sznol, MD.
  • To learn more about current and past SITC Fellowship Award recipients, visit the society's website, SITC Cancer Immunotherapy CONNECT .

Transgene and BioInvent Extend their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors

Retrieved on: 
Tuesday, March 26, 2019
Health, Biotechnology, Oncology, Pharmaceutical, Research, Science, Gene delivery, Branches of biology, Medical specialties, Biology, Molecular biology, Vector, Transgene, Oncolytic virus, Society for Immunotherapy of Cancer, Cancer immunotherapy, SITC, Virus

In November 2018, Transgene and BioInvent presented positive data from their initial collaboration at the Society for Immunotherapy of Cancer (SITC).

Key Points: 
  • In November 2018, Transgene and BioInvent presented positive data from their initial collaboration at the Society for Immunotherapy of Cancer (SITC).
  • Both Transgene and BioInvent believe that these novel multifunctional OVs could be significantly more effective than co-administering an OV and an antibody together.
  • Philippe Archinard, PhD, Chairman and CEO of Transgene, said: We are pleased to extend the scope of our highly productive collaboration with BioInvent.
  • With its proprietary Invir.IOTM, Transgene builds on its expertise in viral vectors engineering to design a new generation of multifunctional oncolytic viruses.